Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –– Verekitug ...

GSK PLC announced Japan?s Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix (GSK?s Recombinant Zoster Vaccine or RZV) for the prevention of ...

GSK plc announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of ...

After Vaibhav, a Class 5 student in Kochi, developed a high fever and persistent dry cough, his parents initially treated it ...

Experts suggest a more ‘whole person’ differential diagnosis when adults do not respond to atopic dermatitis treatment.

AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ...

About the RENEW Phase 2 Trial Rein’s RENEW trial (ClinicalTrials.gov: NCT06968845) is a randomized, placebo-controlled Phase 2 clinical study designed to evaluate the safety, tolerability, and ...

The Biologics License Application for tozorakimab 300mg, administered once every four weeks, has been accepted for Priority Review by the US Food and Drug Administration as an add-on maintenance ...

AstraZeneca announced that full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly ...

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-re ...

Patients describe it in different ways. Some say their vision turns fuzzy during a stressful week at work. Others notice a ...

AstraZeneca announces tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON & TITANIA phase III trials: Cam ...